Aduro IPO pricing values drugmaker at $1 billion

Aduro IPO pricing values drugmaker at billion

The company, whose lead product is in midstage clinical trials for metastatic pancreatic cancer, had previously planned to sell 5 million shares at $ 14-$ 16 per share. … Aduro's experimental STING (Stimulator of Interferon Genes) technology uses a …

Read more on Reuters

Hunter and Gatherer

She is a board affiliate of the Whitney Museum of American Art and Creative Time, among others; she was the executive producer of "Who Gets to Call It Art?", the highly influential and celebrated documentary about the iconoclastic life of museum …

Read more on Huffington Post

Fitch: Strong Results Expected for Hospital Industry in 1Q15

Because of this, strong volume growth has an outsized effect on operating margins and ultimately, cash generation. A return to weaker trends … The above article originally appeared as a post on the Fitch Wire credit market commentary page. The …

Read more on Reuters

Prudential Beazley Real Estate Joins Berkshire Hathaway HomeServices Real …

With the transition, Beazley, REALTORS® agents gain access to Berkshire Hathaway HomeServices' Global Network Platform – a suite of online tools, applications and services – plus ongoing business consultation, professional education and marketing …

Read more on Digital Journal

The post Aduro IPO pricing values drugmaker at $1 billion appeared first on TRJ Marketing.

from WordPress http://ift.tt/1G25X3M

via IFTTT